Rocket Pharmaceuticals, Inc. Accrued Liabilities, Current
Rocket Pharmaceuticals, Inc. (RCKT) had Accrued Liabilities, Current of $2.37 million as of 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2018-03-07
- 2017-12-31: Accrued Liabilities, Current $2.37M.
- 2017-09-30: Accrued Liabilities, Current $2.90M.
- 2017-06-30: Accrued Liabilities, Current $2.42M.
- 2017-03-31: Accrued Liabilities, Current $2.89M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2017-12-31 | $2.37M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $2.90M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $2.42M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $2.89M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $4.25M 10-K · filed 2018-03-07 | $4.42M 10-K · filed 2017-03-16 |
| 2016-09-30 | $3.72M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $3.15M 10-Q · filed 2016-08-10 | |
| 2016-03-31 | $3.24M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $2.51M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $1.53M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $1.27M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $1.05M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $992.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |